Lipkovich Ilya, Citrome Leslie, Perlis Roy, Deberdt Walter, Houston John P, Ahl Jonna, Hardy Thomas
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
J Clin Psychopharmacol. 2006 Jun;26(3):316-20. doi: 10.1097/01.jcp.0000219916.88810.1c.
To determine predictors of substantial weight gain (SWG) during treatment of bipolar disorder with olanzapine, data were pooled from 4 long-term randomized, multicenter studies in patients with bipolar mania or mixed mania (N = 948 at initiation of olanzapine). SWG was defined as gaining 5 kg or 7% of initial weight in 30 +/- 2 weeks. Logistic regression estimated odds ratios associated with early weight gain and baseline risk factors for predicting SWG. A classification system to identify patients at risk for SWG was constructed by recursive data partitioning. Baseline characteristics significantly associated with SWG included younger age, nonwhite ethnicity, lower body mass index (BMI), nonrapid cycling, and psychotic features. Weight gain of 2 or more kg in the first 3 weeks of therapy predicted SWG by 30 weeks (sensitivity = 57%; specificity = 71%). A classification system with thresholds for early weight gain, baseline BMI, and ethnicity further improved SWG predictability (sensitivity = 79%; specificity = 70%). In conclusion, patients with bipolar disorder who gained 2 to 3 kg during the first 3 weeks of treatment with olanzapine, SWG was predicted after 30 weeks of treatment. Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation.
为了确定使用奥氮平治疗双相情感障碍期间显著体重增加(SWG)的预测因素,我们汇总了4项针对双相躁狂或混合性躁狂患者的长期随机多中心研究的数据(奥氮平治疗开始时N = 948)。SWG定义为在30±2周内体重增加5 kg或初始体重的7%。采用逻辑回归估计与早期体重增加相关的比值比以及预测SWG的基线危险因素。通过递归数据分割构建了一个识别SWG风险患者的分类系统。与SWG显著相关的基线特征包括年龄较小、非白人种族、较低的体重指数(BMI)、非快速循环发作以及精神病性特征。治疗前3周体重增加2 kg或更多可预测30周时的SWG(敏感性 = 57%;特异性 = 71%)。一个包含早期体重增加、基线BMI和种族阈值的分类系统进一步提高了SWG的预测性(敏感性 = 79%;特异性 = 70%)。总之,在使用奥氮平治疗的前3周体重增加2至3 kg的双相情感障碍患者,在治疗30周后可预测SWG。如果在治疗开始时BMI接近正常(≤27 kg/m²),早期体重增加不明显的患者后期仍可能有SWG风险。